Diagnostic Histopathology
Volume 14, Issue 8 , Pages 352-365 , August 2008

Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007;2007(57):43–66
  2. Kosary CL. Cancer of the ovary. SEER Survival Monograph National Cancer Institute; 2008;
  3. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. American Registry of Pathology AFIP; 1998;51–79
  4. Auersperg N, Wong AST, Kyung-Chul C, Kang KS, Leung PCK. Ovarian surface epithelium: biology, endocrinology, and pathology. Endo Rev. 2001;22:255–288
  5. Brewer MA, Johnson K, Follen M, Gershenson D, Bast R. Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res. 2003;9:20–30
  6. Lee KR. Surface epithelial stromal tumors of the ovary. In:  Crum CP,  Lee KR editor. Diagnostic obstetric and gynecologic pathology. Philadelphia: Elsevier; 2006;
  7. Alektiar KM, McKee A, Lin O, et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?. Int J Radiat Oncol Biol Phys. 2002;54:79–85
  8. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors: histologic features and prognosis. Cancer. 1998;62:2212–2222
  9. Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer. 1990;65:578–585
  10. Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol. 2001;25:419–432
  11. Camatte S, Morice P, Atallah D, et al. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg. 2002;198:332–338
  12. Prat J, de Nictolis M. Serous borderline tumors of the ovary. A long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26:1111–1128
  13. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol. 2004;191:718–732
  14. Drapkin R, Crum CP, Hecht JL. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum Pathol. 2004;35:1014–1021
  15. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218–224
  16. Naora H. The heterogeneity o epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med. 2007;9:1–12
  17. Umezu T, Hanazono M, Aizawa S, Tomooka Y. Characterization of newly established clonal oviductal cell lines and differential hormonal regulation of gene expression. In Vitro Cell Dev Biol Anim. 2003;39:146–156
  18. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451–456
  19. Joshi MS. Isolation, cell culture and immunocytochemical characterization of oviduct epithelial cells of the cow. J Reprod Fertil. 1988;83:249–261
  20. Smith Sehdev AE, Sehdev PS, Kurman RJ. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol. 2003;27:725–736
  21. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2003;23:41–44
  22. Neri A, Rabinerson D, Kaplan B, Levavi H. Hereditary ovarian cancer. Isr J Med Sci. 1995 Feb;31:172–175
  23. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985–3990
  24. Lee KR, Russell P, Tavassoli FA, et al. Surface epithelial-stromal tumors. In:  Tavassoli FA,  Devilee P editor. Tumors of the breast and female genital organs. Lyon: IARC Press; 2003;p. 117–145
  25. Horiuchi A, Itoh K, Shimizu M, et al. Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol Oncol. 2003;88:309–317
  26. Deligdisch L, Gil J, Kerner H, Wu HS, Beck D, Gershoni-Baruch R. Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer. 1999;86:1544–1550
  27. Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology. 1995;27:367–371
  28. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer. 1994;73:1859–1864
  29. Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer. 2000;89:383–390
  30. Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer. 2002;94:2935–2940
  31. Oral E, Ilvan S, Tustas E, et al. Prevalence of endometriosis in malignant epithelial ovary tumours. Eur J Obstet Gynecol Reprod Biol. 2003;109:97–101
  32. Mhawech P, Kinkel K, Vlastos G, Pelte MF. Ovarian carcinomas in endometriosis: an immunohistochemical and comparative genomic hybridization study. Int J Gynecol Pathol. 2002;21:401–406
  33. Schubert EL, Lee MK, Mefford HC, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet. 1997;60:1031–1040
  34. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect. 1987;73:35–51
  35. Giles JR, Shivaprasad HL, Johnson PA. Ovarian tumor expression of an oviductal protein in the hen: a model for human serous ovarian adenocarcinoma. Gynecol Oncol. 2004;95:530–533
  36. Piek JM, Torrenga B, Hermsen B, et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer. 2003;2:73–78
  37. Rose PG, Shrigley R, Wiesner GL. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol Oncol. 2000;77:319–320
  38. Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol. 2001;80:176–180
  39. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21:4222–4227
  40. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23:127–132
  41. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230–236
  42. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58–64
  43. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?. Obstet Gynecol. 2005;106:1327–1334
  44. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161–169
  45. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma (STIC): Its potential role in primary peritoneal serous carcinoma (PPSC) and serous cancer prevention. J Clin Oncol, in press.
  46. Roh M, Kindelberger D, Crum CP. Tumor presentation in pelvic serous cancer: a clue to pathogenesis?. Mod Pathol. 2008;21:221A
  47. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26–35
  48. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol. 2008;109:168–173
  49. Parast MM, Drapkin R, McKeon F, et al. Evidence that high and low grade ovarian serous tumors reflect different cells of origin. Abstract, United States Canadian Academy of Pathology; 2006.
  50. Motoyama N, Naka K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev. 2004;14:11–16
  51. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27:1–9

PII: S1756-2317(08)00094-7

doi: 10.1016/j.mpdhp.2008.06.009

Diagnostic Histopathology
Volume 14, Issue 8 , Pages 352-365 , August 2008

Article Tools

* Image Usage & Resolution